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Abstract
Elevated factor VII (FVII) level is a risk factor for coronary artery disease (CAD). We investigated the role of R353Q poly-
morphism in the F7 gene in 139 Indian families with CAD, comprising of 222 aﬀected subjects, 105 unaﬀected subjects
and 126 aﬀected sibling pairs. Plasma per cent FVIIc activity (FVII.c activity) diﬀered significantly across R353Q genotype
(P < 0.0001). Frequency of subjects with RR and QQ genotypes were higher in 4th quartile and 1st quartile of FVII.c activity,
respectively (P < 0.0001). F7 R353Q SNP was able to explain up to 7% of variation in FVII.c activity by regression analysis
and an additive genetic component of variance of 28.04% by heritability analysis. Quantitative trait loci analysis showed
suggestive linkage evidence of F7 SNP with per cent FVII.c activity (LOD score −1.82; P = 0.002). Individuals with RR and
RQ genotypes carried an OR of 2.071 (95% c.i. = 1.506–2.850) and 2.472 (95% c.i. = 1.679–3.641), respectively, towards
CAD risk. There was significant correlation of FVII.c activity with lipid markers, particularly among those with RR and
RQ genotype after covariate adjustment. In conclusion, the F7 R353Q SNP appears to moderately influence plasma FVII.c
activity and risk of CAD in Indians.
[Shanker J., Perumal G., Maitra A., Rao V. S., Natesha B. K., John S., Hebbagodi S. and Kakkar V. V. 2009 Genotype–phenotype relationship
of F7 R353Q polymorphism and plasma factor VII coagulant activity in Asian Indian families predisposed to coronary artery disease. J.
Genet. 88, 291–297]
Introduction
Factor VII (FVII.) is a key component in the extrinsic coagu-
lation pathway (Rao and Rapaport 1988) Both genetic and
environmental factors influence plasma FVII levels. Age,
obesity and food habits, as well as use of oral contracep-
tives and onset of menopause among females are some of
the commonly reported non-genetic factors (Balleisen et al.
1985; Meade et al. 1986; Scarabin et al. 1996). Levels
of plasma FVII show inter-individual diﬀerences as well as
variation within populations (Meade et al. 1977; Thompson
et al. 1987).
*For correspondence. E-mail: jayashreeshanker@triindia.org.in.
Studies on large families have assisted in determining the
genetic contribution towards variation in FVII levels. The
non-synonymous R353Q single nucleotide polymorphism
(SNP) in exon 8 in the F7 gene has been shown to influence
FVII levels (Green et al. 1991). The R353Q SNP, which
involves the replacement of the amino acid arginine (R) by
glutamine (Q) due to the substitution of guanine with ade-
nine at the codon 353 position in the F7 gene, was shown to
account for over 20% of the variance in FVII levels (Green
et al. 1991). Strong linkage disequilibrium (LD) has been
observed between the R353Q SNP and a10-bp ins/del poly-
morphism (Liu et al. 2002). Molecular dissection of a 15-
kb-genomic region around the F7 gene was able to identify
49 SNPs, of which four to seven functional variants were
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shown to exert a regulatory control on circulating FVII levels
(Soria et al. 2005). While there is consensus on the genotype
specific eﬀect of the F7 gene variants on FVII levels, their
role in CAD is debatable (Doggen et al. 1998; Feng et al.
2000; Batalla et al. 2001). The aim of the present study was
to look at the association and linkage between the R353Q
polymorphism in the F7 gene and plasma factor VII. coagu-
lant activity (FVII.c activity) and CAD status in Asian Indian
families predisposed to CAD. In addition, the relationship of
the F7 SNP with other atherothrombotic blood phenotypes
was assessed.
Materials and methods
A total of 139 families consisting of 327 participants, 222 af-
fected and 105 unaﬀected members, were recruited in the on-
going Indian Atherosclerosis Research Study (IARS), which
investigates the molecular basis of atherothrombosis in In-
dian families with strong family history of CAD. Families
were enrolled through the proband who had angiographically
proven CAD and diagnosed as stable angina/unstable angina
or had an episode of myocardial infarction based on cardio-
logical diagnosis. The age at onset of CAD was ≤ 60 years
for males and ≤ 65 years for females. There were 194 males
(87.4%) and 28 females (12.6%) in the CAD aﬀected group
and 49 males (46.7%) and 56 females (53.3%) in the unaf-
fected group, respectively.
Around 126 aﬀected sibling pairs (ASPs) were selected
from 87 IARS families for linkage analysis. All study par-
ticipants provided fasting blood and urine samples as well
as clinical and relevant personal information by informed,
signed, voluntary consent. The institutional ethics commit-
tee, which follows the Indian Council of Medical Research
guidelines on conduct of research on human subjects, ap-
proved the IARS protocol.
Laboratory investigations
Genomic DNA was extracted using the salting-out proce-
dure (Miller et al. 1988). Genotyping of the F7 R353Q SNP
(rs6046) was performed according to the procedure reported
by Green et al. (1991). In short, the genomic region encom-
passing the polymorphic site in exon 8 of the F7 gene was
PCR amplified, digested with Msp1 restriction enzyme and
resolved on a 2% agarose gel. Genotyping was confirmed by
bi-directional sequencing of the amplified 312-bp product in
five samples using Big Dye Terminator 3.1 sequencing kit
and 3130XL Genetic Analyzer (Applied Biosystems, Fos-
ter City, USA). Figure 1a depicts a gel picture of the three
genotypes, RR, RQ and QQ, whereas figure 1b shows the
sequence variation in a heterozygote.
Various atherothrombotic blood phenotypes were as-
sayed using plasma samples. Coagulation parameters,
namely FVII.c activity (expressed as per cent activity), fib-
rinogen (g/L) and prothrombin time (PT expressed in sec-
onds) were analysed by clotting assays on the ACL 300 au-
tomated coagulation analyzer (IL Systems, Milano, Italy).
Lipid markers (TC, TG, HDL-C (mg/dL), lp(a) (mg/L), Apo
AI, ApoB (g/L)) and hsCRP (μg/dL) were estimated on a
Clinical Chemistry analyzer (Hoﬀman La Roche, Switzer-
land) while PAI-1 (ng/mL) and IL6 (pg/mL) were assayed
by ELISA method.
Linkage analysis
ASP analysis was used to test for linkage between CAD and
the F7 R353Q genotype (Blackwelder and Elston 1985). Ap-
propriate input files were created using the MEGA2 program
(Mukhopadhyay et al. 2005). Single-point-linkage analy-
sis was performed using the SAGE version 5.3.1 package
(Elston and Gray-McGuire 2004). Significant presence of
linkage was assigned based on the criteria of Kruglyak et al.
(1996). Mean proportion of allele sharing (pi), identity by
descent (IBD) between the ASPs, was calculated using the
GENIBD program in SAGE and was considered to be sig-
nificant if the estimated value was greater than 0.50. Quan-
titative trait analysis (QTL) of the F7 SNP and FVII.c activ-
ity was performed using MERLIN program (Abecasis et al.
2002). Age, gender and body mass index (BMI) were used
as covariates.
Figure 1a. FV11 R353Q genotypes resolved on 2% agarose gel. M, 100-bp DNA ladder; genotypes are
resolved based on the presence or absence of Msp1 restriction enzyme cutting site. ‘R’ allele has two cutting
sites and ‘Q’ allele has no cutting site. RR genotype (205 bp), RQ genotype (272 and 205 bp), QQ genotype
(272 bp).
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Figure 1b. Sequence of FVII R353Q region showing
the RQ (AG) heterozygote at base position 135.
Association studies
The CAD aﬀected participants (n = 222) and their unaf-
fected siblings (n = 105) were included for the association
studies. All quantitative traits were expressed as mean ±
s.e. Conformity to Hardy–Weinberg equilibrium was deter-
mined by the χ2 test. Student’s t-test or one-way ANOVA
was employed to calculate mean diﬀerences for the contin-
uous variables, while Pearson’s χ2 test was used to estimate
the diﬀerences in proportions for discrete variables includ-
ing the R353Q genotypes. Estimation of correlation between
FVII.c activity and other atherothrombotic phenotypes were
performed by partial two-tailed correlation test after adjust-
ing for age and gender. Variance component analysis was
used to estimate the extent of genetic contribution of the F7
SNP to the variance in per cent FVII.c activity. Multivariate
analysis was performed for all quantitative variables across
the R353Q genotypes and gender. Factors such as lipids, co-
agulation markers, inflammatory markers, PAI-1, BMI and
waist: hip ratio were analysed with FVII.c activity in each of
these groups, using age as covariate to understand the rela-
tionship of the various atherothrombotic variables to plasma
FVII.c activity. Discriminant analysis was performed across
the F7 genotype for males and females separately. Both sim-
ple and multiple linear regression analyses were used to ex-
plain the contributory variables that influenced FV11 levels.
The extent of association of F7 SNP with CAD status was
estimated using the logistic regression model with QQ geno-
type as the reference. The Q–Q plot was used to test for nor-
mality of distribution for the quantitative variables. Values
with skewed distribution were log-transformed prior to anal-
ysis. The number of diseased coronary vessels, mean age at
onset and event score (ischemic heart disease with symptoms
of chest pain −1, stable angina −2 and unstable angina / MI
−3) defined CAD severity scoring. A nominal P value of
0.05 or less was considered statistically significant. SPSS
version 13 for Windows (SPSS, Chicago, USA) was used for
the analyses.
Results
The distribution of the various characteristics and phenotypic
markers in the CAD aﬀected and unaﬀected subjects is pro-
vided in table 1. Mean values of most biomarkers; namely
lipids and pro-coagulant factors, were significantly higher
in the unaﬀected than the aﬀected family members and this
trend remained when separately tested for subjects who were
not on statins (n = 172) (data not shown). Mean FVII.c ac-
tivity were lower in CAD subjects (104.45± 1.59%) than the
unaﬀected group (116.87± 2.3%) (P < 0.001). Frequency of
diabetes, hypertension and smoking was higher among the
aﬀected (51.8%, 45.9%, 47.3%) than the unaﬀected subjects
(19.0%, 25.7%, 18.1%) (P < 0.0001).
The mean age at onset of CAD was 50.28 (±0.65) years
for males and 52.69 (±1.83) for the female cases. Two or
more vessel disease was present in 78% of the CAD patients
with over 64% suﬀering from unstable angina or myocar-
dial infarction event (event score = 3). The proportion of
aﬀected subjects who were taking medication was signif-
icantly higher than the unaﬀected subjects: lipid-lowering
drugs (statins: 65% vs 3%), anti-hypertensive agents (ACE
inhibitor/beta blocker: 41%/30% vs 11%/13%) and hypo-
glycemic agents (38% vs 13%), respectively.
Linkage studies
There was no evidence of linkage between the R353Q SNP
and CAD using 126 ASPs in the IARS cohort (LOD score
0.1376). There was no significant deviation in the proportion
of mean allele sharing (pi = 0.51) between the ASPs. Sug-
gestive evidence of linkage was obtained between the R353Q
SNP and FVII.c activity (LOD score 1.82; P = 0.002) by
QTL analysis.
F7 genotype–phenotype analysis
The F7 R353Q SNP was in Hardy–Weinberg equilibrium
(P > 0.05) in the whole data as well as in the aﬀected and
unaﬀected groups. The three genotypes were confirmed by
sequencing of the region of interest in five samples. Al-
lele and genotype frequencies showed similar distribution in
the aﬀected and unaﬀected subjects and across gender with
a minor allele frequency of 0.28–0.29. The frequency of
QQ genotype was higher in the unaﬀected subjects (12.4%;
n = 13) as compared to the aﬀected group (7.7%; n = 7).
However, this diﬀerence was not statistically significant.
R353Q genotype and plasma FVII.c activity
There was significant diﬀerence in the mean plasma FVII.c
levels across RR, RQ and QQ genotypes in both aﬀected
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Table 1. Distribution of clinical and biomarker data between CAD
aﬀected and unaﬀected family members (mean ± s.e.).
Characteristic CAD Non CAD P value*
Number 222 105 –
Age, y 55.2 ± 0.6 49.4 ± 1.0 < 0.001
Sex, % male 80 20 < 0.0001
BMI, kg/m2 25.71 ± 0.28 26.21 ± 0.39 0.31
WHR 0.95 ± 0.003 0.91 ± 0.005 < 0.0001
Diabetes, % 85 15 < 0.0001
Hypertension 79 21 < 0.0001
Smoking, % (males) 85 15 < 0.0001
Alcohol, % 18.1 15.2 0.32
SBP, mm Hg 127.9 ± 1.13 130.8 ± 1.7 0.16
DBP, mm Hg 82.7 ± 0.59 83.6 ± 0.91 0.37
TC (mg/dl) 151.63 ± 2.6 185.86 ± 3.9 < 0.0001
TG (mg/dl) 151.08 ± 4.6 171.1 ± 11.0 0.049
HDL-c (mg/dl) 34.5 ± 0.6 36.1 ± 0.8 0.084
LDL-c (mg/dl) 86.84 ± 2.3 117.7 ± 3.68 < 0.0001
ApoA1 (g/l) 1.12 ± 0.02 1.25 ± 0.03 < 0.0001
ApoB (g/l) 0.93 ± 0.02 1.18 ± 0.04 < 0.0001
Lp (a) 28.13 ± 2.13 21.33 ± 1.95 0.047
LVII.c activity, % 104.45 ± 1.59 116.87 ± 2.3 < 0.0001
PT, sec 12.5 ± 0.07 12.02 ± 0.13 < 0.0001
Fibrinogen 4.15 ± 0.08 4.23 ± 0.09 0.54
IL6 6.9 ± 1.6 4.8 ± 0.8 0.39
hsCRP 3.39 ± 0.35 4.12 ± 0.52 0.32
PAI-1 52.51 ± 2.81 63.98 ± 5.35 0.04
ApoA1, apolipoprotein A1; Apo B, apolipoprotein B; BMI, body
mass index; FVII.c, factor VII coagulant activity; HDL-c, high den-
sity lipoprotein-cholesterol; Lp (a), lipoprotein (a), LDL, low den-
sity lipoprotein; PT, prothrombin time, WHR, waist–hip ratio.
*Figures in bold indicate significant P value.
Figure 2. Mean FVII.c levels (%) across the R353Q genotypes
among the CAD aﬀected and unaﬀected subjects.
(113.53 ± 23.47%, 97.57 ± 18.16% and 78.47 ± 23.66%)
and unaﬀected (125.38 ± 21.47%, 112.19 ± 18.80% and
93.15 ± 26.01%) subjects, respectively (P < 0.0001) (figure
2). Individuals with one or two R alleles showed an average
of 20%–30% higher FVII.c activity when compared to those
harbouring the Q allele. Due to the diﬀerence between the
two homozygotes, RR and QQ, the additive genetic compo-
nent was manually estimated to be 28.04% using variance
component analysis.
Simple linear regression analysis showed that the F7
R353Q genotype was able to independently explain up to
18.7% of variation in FVII.c activity (P < 0.0001). When
the association of the F7 SNP was analysed across the four
quartiles of plasma factor VII activity in the whole dataset,
over 36% of subjects with RR genotype belonged to the 4th
quartile and only 10.4% were in the 1st quartile. Conversely,
around 63.3% of individuals with QQ genotype were in the
1st quartile, while only 1.3% was in the 4th quartile (χ2
with 6 d f = 66.63; P < 0.0001) (table 2). This signifi-
cant trend was retained when aﬀected and unaﬀected subjects
were analysed independently (data not shown).
R353Q genotype and CAD status
Individuals with RR genotype showed an OR of 2.07 (95%
c.i. = 1.51–2.85) when tested against the QQ genotype for
CAD risk while those with the RQ genotype showed an OR
of 2.47 (95% c.i. = 1.68–3.64) employing logistic regression
analysis (table 3). No significant association was observed
between the R353Q genotypes and the mean age at onset,
number of diseased vessels or event score.
Table 2. Distribution of F7 R353Q genotypes across the FVII.c
quartiles.
Quartile distribution of FVII.c activity*
1 2 3 4
RR Genotype N (%) 18 (10.5) 42 (24.4) 50 (29.1) 62 (36.0)
RQ Genotype N (%) 45 (36.0) 37 (29.6) 29 (23.2) 14 (11.2)
QQ Genotype N (%) 19 (63.3) 5 (16.7) 1 (3.3)
χ2 = 66.63 (6 d.f.); P < 0.0001. *The figures in bold indicate max-
imum frequency of individuals with RR genotype in the 4th quartile
and minimum frequency of individuals with QQ genotype in the 1st
quartile of FVII.c activity.
Table 3. Association of F7 R353Q SNP with CAD af-
fected status.
Genotype P value* Odds ratio (95% c.i.)
QQ genotype – –
(reference genotype)
RR genotype < 0.0001 2.07 (1.51–2.85)
RQ genotype < 0.0001 2.47 (1.68–3.67)
*Figures in bold indicate significant P values.
Genotype–phenotype relationship of F7 R353Q genotype, plasma
FVII.c activity and atherothrombotic phenotypes
Correlation estimation of FVII.c activity and other athero-
thrombotic biomarkers across the F7genotypes showed that
there was significant correlation for some markers only in the
group with RR genotype and to a certain extent, the RQ geno-
type, while there was no correlation with any of the biomark-
ers within the QQ genotype group (see table 1 in electronic
supplementary material at http://www.ias.ac.in/jgenet/).
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Gender showed significant influence on plasma FVII.c
activity by multiple linear regression analysis with the F7
SNP contributing to over 7% of variation. PT (45%), LDL-
c (5%), TC (3%) and PAI-1 (2%) were the other significant
contributors in this dataset. Multivariate analysis of variance
showed a significant eﬀect of gender and genotype on FVII.c
activity. HDL-c, BMI and WHR, and PT (see table 2 in elec-
tronic supplementary material). There was significant asso-
ciation in the pattern of distribution of TC and LDL-c across
the quartiles of FVII.c activity (P < 0.01) (see table 3 in elec-
tronic supplementary material). Discriminate analysis across
the F7 genotypes and gender showed that 80% of the vari-
ability was extracted by the first function (P < 0.0001) de-
fined by FVII.c activity and PT with standardized discrimina-
tion coeﬃcient values of r = 0.691 and 0.393, respectively.
Discussion
Polymorphisms within the F7 gene undoubtedly contribute
to plasma FVII.c activity, although there is considerable dif-
ference in the relative extent of their influence on the pheno-
type across populations. We have observed a high heritabil-
ity (76%) and a low spouse pair correlation (r = 0.038) for
plasma FVII.c activity in the IARS cohort (508 families and
2305 individuals) indicating the significant contribution of
genetic factors towards FVII.c activity. The additive genetic
variance of the F7 SNP was around 28%, suggesting that this
SNP may be an important variant that influences FVII.c ac-
tivity.
The R353Q SNP accounts for over 20% of the variation
in FVII activity among Caucasians (Green et al. 1991; Lane
et al. 1996) and around 5%–11% among Asians (Saha et al.
1994) and this association is dependent on gender. While
the F7 R353Q SNP independently accounted for over 18%
of the variability in the FVII.c activity in our cohort, inclu-
sion of other correlating factors such as lipids and coagula-
tion factors reduced the contribution of the F7 SNP to 7%.
This polymorphism was the strongest predictor of FVII anti-
gen levels and explained up to 7.7% of the total variance in
the Framingham study (Feng et al. 2000). A higher propor-
tion of subjects with RR and QQ genotypes in the 4th and 1st
quartiles of per cent FVII.c activity, respectively, provide ev-
idence of influence of the R allele on plasma FVII.c activity.
However, the magnitude of eﬀect is low, given the fact that
the overall contribution by this SNP is only 7% in the present
study.
QTL analysis on ASPs showed suggestive evidence of
linkage of the R353Q locus to FVII.c activity but not with
CAD. This may be attributable to the small numbers of ASPs
analysed in the study and/or due to the presence of other
SNPs in close proximity to the R353Q locus that may im-
part a greater eﬀect on FVII.c activity in circulation. This
warrants further investigation.
We observed a minor allele (Q) frequency of 0.28, which
is comparable to the prevailing frequency in the Caucasian
population (Bernardi et al. 1997). The RR and the RQ geno-
type were significantly associated with CAD status in com-
parison to the QQ genotype based on the estimated odds ratio
which indicates the relative influence of this F7 SNP on CAD
risk. Also, the frequency of the QQ genotype was higher in
the unaﬀected group than the aﬀected group, though the dif-
ference was not statistically significant. As the present com-
parison has been from a family-based cohort of related sam-
ples, it would be worthwhile to confirm these preliminary
results, independently, on a larger study based on population
bases, case–control analysis.
Genotype-specific association of plasma FVII levels with
lipids, mainly triglycerides, has been reported among Cau-
casian in non-fasting states (Humphries et al. 1994; Lane et
al. 1996) and among Gujarati–Indian population in fasting
state (Saha et al. 1994) particularly in those with RR or RQ
genotypes. We observed a similar trend wherein, following
covariate adjustment, there was significant correlation of per
cent FVII.c activity with lipids and other prothrombotic fac-
tors only among those with the RR and to some extent the
RQ genotypes but not for the QQ genotype (see table 1 in
electronic supplementary material).
Lipids and procoagulant factors including FVII.c were
higher among the unaﬀected members and in the female co-
hort in our study. Several factors may have contributed to
this observation. Firstly, our cohort has been selected from
a family-based study where strong genetic relationship and
shared environmental background between siblings could act
as potential confounders. Females have an inherent tendency
for higher biomarker levels than males; however, the inci-
dence of CAD is kept in check among young women in their
reproductive age, probably due to the protective influence
of oestrogen against heart diseases that slowly diminishes
in post-menopausal women (Scarabin et al. 1996). In the
present study, out of total 222 CAD aﬀected subjects, only
13% (n = 28) were females, whereas more than half of the
105 unaﬀected members constituted females (53%; n = 56).
The mean BMI levels and other proatherogenic and coag-
ulation markers were elevated in females than in males in
our cohort. Whether this increase in biomarker levels can
be attributed to the influence of the higher BMI levels ob-
served in females is a matter that warrants further investi-
gation but may to a certain extent explain the predominance
of biomarker levels in the unaﬀected subjects who have a
greater proportion of females in their midst.
Although, over 63% of the aﬀected cohort was on lipid-
lowering therapy as compared to 3% of the unaﬀected sub-
jects, statins did not appear to influence the biomarker levels
as evinced by the independent analysis conducted on those
subjects who were not on lipid-lowering therapy.
Factor VII.c activity has been considered as a risk fac-
tor for coronary heart disease in the presence of smoking,
fibrinogen and lipids in the PROCAM study (Junker et al.
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1997) while the risk of MI that has been associated with
the haplotypes in the F7 gene through their intermediary in-
fluence on BMI, low HDL-c etc. (Reiner et al. 2007). Our
present family-based study suggests a similar trend wherein
high coagulant activity of FVII, in the presence of other
atherothrombotic traits, particularly the lipids and traditional
risk factors may exert a combined influence on CAD status
with each factor contributing in a small way to enhance the
overall risk of CAD in the Asian Indian population.
In conclusion, both association and linkage studies in-
dicate the significant influence of F7 R353Q genotype on
plasma FVII.c activity while its association with CAD may
be indirectly influenced by the presence of other intermedi-
ary risk phenotypes.
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